Cosciens Biopharma Inc (CSCI)
1.60 x 2 6.00 x 1
Post-market by (Cboe BZX)
4.10 +0.26 (+6.77%) 07/17/25 [NASDAQ]
1.60 x 2 6.00 x 1
Post-market 4.10 unch (unch) 15:35 ET
for Thu, Jul 17th, 2025
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
Cash Flows From Operating Activities | |||||
Net Income | -15,309 | -3,485 | -22,727 | -8,368 | -5,118 |
Depreciation Amortization | 751 | 1,443 | -1,569 | -1,525 | 1,489 |
Income taxes - deferred | N/A | N/A | 831 | N/A | N/A |
Accounts receivable | -1,683 | 1,856 | 592 | 120 | -1,023 |
Other Working Capital | -2,514 | 58 | 604 | 2,500 | 2,402 |
Other Operating Activity | 4,187 | -2,454 | 8,589 | -1,308 | -1,879 |
Operating Cash Flow | $-14,568 | $-2,582 | $-13,680 | $-8,581 | $-4,129 |
Cash Flows From Investing Activities | |||||
PPE Investments | -1,161 | -722 | -11 | -29 | 6 |
Net Acquisitions | 26,037 | N/A | N/A | N/A | N/A |
Purchase Sale Intangibles | N/A | N/A | N/A | -609 | N/A |
Other Investing Activity | 207 | -8 | -1 | -629 | 50 |
Investing Cash Flow | $25,083 | $-730 | $-12 | $-658 | $56 |
Cash Flows From Financing Activities | |||||
Common Stock Issued | N/A | 13 | N/A | 54,287 | 23,500 |
Other Financing Activity | -588 | -370 | -118 | -3,250 | -3,032 |
Financing Cash Flow | $-588 | $-357 | $-118 | $51,037 | $20,468 |
Exchange Rate Effect | -212 | 157 | -879 | -769 | 38 |
Beginning Cash Position | 6,678 | 10,190 | 65,300 | 24,271 | 7,838 |
End Cash Position | 16,393 | 6,678 | 50,611 | 65,300 | 24,271 |
Net Cash Flow | $9,715 | $-3,512 | $-14,689 | $41,029 | $16,433 |
Free Cash Flow | |||||
Operating Cash Flow | -14,568 | -2,582 | -13,680 | -8,581 | -4,129 |
Capital Expenditure | -1,161 | -722 | -11 | -30 | N/A |
Free Cash Flow | -15,729 | -3,304 | -13,691 | -8,611 | -4,129 |